No Data
To build a resource-recycling model for cosmetic containers, collaboration with Albione has begun NEW.
Mitsubishi Chemical Group*1 (hereinafter referred to as "the Group") will begin collaboration with Albion Co., Ltd. (hereinafter referred to as "Albion"), which manufactures and sells high-end Cosmetics, aiming to build a resource-circulating model for cosmetic containers. Waste materials generated at Albion will be chemically recycled*2 by the Group and regenerated into new cosmetic containers. Cosmetic containers are delivered to Albion by container manufacturers with plastic cushioning materials to prevent scratches and to avoid dust contamination.
[Tanabe Mitsubishi Pharma] Obtained approval for the additional efficacy of 'Cariprazine' (MP-214), a treatment for schizophrenia and bipolar disorder, as an adjunctive therapy for major depressive disorder in Thailand NEW
Mitsubishi Chemical Group's Tanabe Mitsubishi Pharma Corporation (headquarters: Chuo Ward, Osaka City, Representative Director: Akihiro Tsujimura, hereinafter referred to as "Tanabe Mitsubishi Pharma") announced that its consolidated subsidiary, Mitsubishi Tanabe Pharma (Thailand) Co., Ltd., regarding Cariprazine (generic name, clinical trial code: MP-214, dopamine D3/D2 receptor partial agonist, Thai product name: Reagila) in Thailand.
【Mitsubishi Tanabe Pharma】 Announcement of awareness survey results for obese patients, doctors, and the general public - About 70% of the general public and nearly 90% of obese patients believe that "obesity is self-responsibility." Among them, about two
87% of obesity patients, 64% of doctors, and 70% of the general public answered that obesity is "the individual's responsibility." It was observed that 34% of obesity patients and 41% of the general public, despite being presented with scientific evidence stating that "obesity and obesity-related conditions arise from multiple factors," do not "agree" that it is "difficult to solve solely through one’s own efforts." 78% of obesity patients, 87% of doctors, and 69% of the general public believe that the treatment of obesity should be considered equivalent to or even more important than the treatment of other diseases.
Plant-derived Resin prepreg has obtained ISCC PLUS certification ~ Contributing to reducing environmental impact from sports, Leisure, mobility to industrial applications ~ NEW
Mitsubishi Chemical Group (hereinafter referred to as "the Group") announces that in November 2024, the prepreg made from plant-based Resin manufactured at the Mitsubishi Chemical Tokai Plant (Aichi area) has obtained the ISCC (International Sustainability and Carbon Certification) PLUS certification, which is one of the international certification systems for sustainable products.
[Mitsubishi Tanabe Pharma] The approval application for the Parkinson's disease treatment candidate ND0612 has been accepted by the European Index (EMA) NEW.
Mitsubishi Chemical Group's Tanabe Mitsubishi Pharma Corporation (Headquarters: Chuo-ku, Osaka, Representative Director: Akihiro Tsujimura, hereinafter referred to as "Tanabe Mitsubishi Pharma") received notification on February 20 (local time) that the European Medicines Agency (EMA) accepted the application for marketing authorization for ND0612, which is being developed as a treatment candidate for Parkinson's disease with diurnal variability of motor symptoms. ND0612 is a wholly owned subsidiary of Tanabe Mitsubishi Pharma.
Mitsubishi Chemical G, Mitsui & Co., etc. [List of stock materials from the newspaper]
*Mitsubishi Chemical Group <4188> expands semiconductor materials for post-processing, suppressing sealing and thermal expansion (Nikkan Kogyo, front page) - ○ *Mitsui & Co. <8031> invests in U.S. synthetic fuels, eyeing decarbonization in the trucking industry (Nikkan Kogyo, page 4) - ○ *Kansai Electric Power <9503> reviews plans for the removal of spent nuclear fuel and presents them to Fukui Prefecture (Nikkan Kogyo, page 4) - ○ *Unitika <3103> receives 20 billion yen from REVIC and promotes structural reform (Nikkan Kogyo, page 4) - ○ *Miyoshi Oil & Fat <4404> announces new medium-term plan with capital investments of 20 billion yen.
104476495 : h
九洲哥 : Continue up... don't stop
